Secaucus, NJ, January 13, 2015
Caligor Rx, a leader in global specialty pharmaceutical services, today announced that it has named Karen Frascello to the new position of Vice President of Business Development & Marketing for the Company’s Global Access Programs (GAP). GAP is Caligor’s term for programs that are sometimes referred to as “named patient,” “expanded access,” “early access” or “compassionate use.” These programs are specifically intended for patients who have exhausted their treatment options and for whom appropriate therapies exist outside standard commercial channels. A GAP can be established for an individual patient or for a group of patients.
“Karen brings a wealth of expertise in leading business development activities for global patient access and compassionate use programs,” said Caligor Managing Director Tammy Bishop. “Her 20 years of biopharma industry experience will be instrumental in helping our clients arrive at optimal solutions to provide investigational and unlicensed medicines to patients in a compliant and efficient manner.”
Before joining Caligor, Ms. Frascello served as Director of Global Business Development at Idis Inc., where she guided pharma and biotech companies through the strategic planning process for developing global patient access and compassionate use programs. From 2006 to 2010 she was Executive Director of Business Development for Professional Detailing Inc., a leading US pharmaceutical contract sales organization. She began her career as a pharmaceutical sales representative and was subsequently promoted into sales management. Ms. Frascello had oversight for primary care sales teams at Pfizer and served as a Regional Sales Director for AstraZeneca, managing the respiratory portfolio.
“I am delighted to join Caligor Rx as we expand our service offerings for pharmaceutical and biotech companies,” Ms. Frascello said. “I look forward to leveraging my experience to help our clients meet the growing demand for early or pre-launch access to potentially life-saving investigational treatments. Our Global Access Programs, which are supported by experts within our regulatory and operational teams, ensure ethical, controlled delivery of investigational therapies into countries worldwide.”
Ms. Frascello graduated with honors and holds a BS in Biology from the University of Akron. She is the Co-Chair of the Patient Access Committee for Global Genes/RARE Project, a leading rare disease advocacy organization for patients, caregivers and advocates.
About Caligor Rx
Caligor Rx is a global specialty pharmaceuticals services business focused primarily on sourcing and supplying drugs for worldwide clinical trials. The Company is dedicated to serving the pharmaceutical and life science industries as well as patients with specialty needs. Caligor is certified as a Women’s Business Enterprise (WBE) by the Women’s Business Enterprise National Council, the largest third-party certifier of businesses owned, controlled and operated by women in the U.S. To learn more about implementing a Global Access Program, contact Caligor at (212) 988-0590 or CaligorGAP@caligorrx.com.